Cogent Biosciences, Inc.
COGT
$11.40
-$0.02-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.73% | 22.93% | 24.83% | 22.88% | 34.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.08% | 26.63% | 26.58% | 36.75% | 44.33% |
| Operating Income | -20.08% | -26.63% | -26.58% | -36.75% | -44.33% |
| Income Before Tax | -23.37% | -24.95% | -27.54% | -33.75% | -51.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.37% | -24.95% | -27.54% | -33.75% | -51.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.37% | -24.95% | -27.54% | -33.75% | -51.21% |
| EBIT | -20.08% | -26.63% | -26.58% | -36.75% | -44.33% |
| EBITDA | -20.21% | -26.86% | -26.77% | -37.10% | -44.72% |
| EPS Basic | 99.91% | 2.76% | 0.23% | -0.75% | -131,797.67% |
| Normalized Basic EPS | 99.91% | 8.48% | 0.25% | -0.76% | -131,812.17% |
| EPS Diluted | 99.91% | 2.76% | 0.23% | -0.75% | -131,797.67% |
| Normalized Diluted EPS | 99.91% | 8.48% | 0.25% | -0.76% | -131,812.17% |
| Average Basic Shares Outstanding | 139,706.04% | 28.50% | 27.85% | 32.76% | -99.89% |
| Average Diluted Shares Outstanding | 139,706.04% | 28.50% | 27.85% | 32.76% | -99.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |